Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target genomic adenine within double-stranded DNA at near-match protospacer sites with NRCH PAMs refers to unintended sites of genetic modification by Adenine Base Editors (ABEs) utilizing engineered Cas9 variants. These variants, such as SpCas9-NRCH, are designed to recognize a broader range of Protospacer Adjacent Motifs (PAMs) beyond the standard NGG, specifically NRCH (where R is A/G and H is A/C/T) (Miller et al., 2020, Nature Biotechnology). When an ABE is directed to a target site, it may also bind to and deaminate adenines at "near-match" genomic locations that share high sequence homology with the guide RNA (Gaudelli et al., 2017, Nature). This process converts adenine to inosine, which is subsequently treated as guanine by DNA polymerase, resulting in permanent A•T-to-G•C transitions (Rees & Liu, 2018, Nature Reviews Genetics). Such off-target activity is a primary safety concern in genome editing, as it can lead to deleterious mutations, loss of tumor suppressor function, or activation of oncogenes (Zuo et al., 2019, Science). Consequently, identifying and quantifying these sites using high-throughput sequencing methods like GUIDE-seq or DISCOVER-seq is essential for the clinical translation of base editing technologies (Wienert et al., 2019, Science).
Unintended adenosine deamination by a CRISPR-guided base editor at non-target genomic loci, leading to A-to-G transitions.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target genomic adenine.